Tag: PD-L1

HalioDx receives CLIA Compliance for Immunoscore® Colon

| June 21, 2017 | 0 Comments

HalioDx receives CLIA Compliance for its laboratory based in Marseille Immunoscore® Colon, is now available to US patients in selected states with a turnaround time of 10 days Marseille, June 21, 2017 – HalioDx announced today that the company is compliant under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) for its Marseille-based full service […]

Continue Reading

FDA Approval of Immunotherapy For MSI-High or Mismatch Repair Deficient Tumors

| June 5, 2017 | 0 Comments

Last month the FDA approved pembrolizumab (KEYTRUDA) for adult and pediatric patients with with metastatic or unresectable, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment. KEYTRUDA has also been approved fro MSI-H or dMMR colorectal cancers that have progressed following treatment with conventional chemotherapies. The immunooncology/immunotherapy story is fascinating. […]

Continue Reading

ASI’s HiPath™ For Computer-Assisted PD-L1 Interpretation

| May 12, 2017 | 0 Comments

HiPath™ Supports Pathologists with Advanced Image Analysis of PD-L1 Assays CARLSBAD, CA, May 11, 2017 — Applied Spectral Imaging (ASI), a global leader of computer-assisted microscopy, introduces HiPath imaging and analysis of PD-L1 assays. PD-L1 is seen as the current breakthrough therapeutic target in immuno-oncology. Following recent clinical advances, PD-L1 expression has become a key factor in […]

Continue Reading

Come Challenge the Computer with Visiopharm at USCAP 2017

| March 3, 2017 | 0 Comments

Join Visiopharm at USCAP 2017 and learn about how we are transforming pathology! Come see demonstrations of Analysis of PD-L1 and CD Markers within the Tumor Micro-Environment Visualize and quantify biomarker expression with heatmaps and automated hot-spot detection The new, ultra-fast viewer which can be integrated into your digital pathology workflow Visit our booth to […]

Continue Reading

Will Not Using Image Analysis in Pathology be Perceived as Irresponsible? 

| February 1, 2017 | 0 Comments

Originally published by Simon Häger, Product Manager Sectra Digital Pathology Solution at Sectra.com.  It is hard to argue with any of the points raised here by Simon. No doubt image analysis will enable what we do to do it better. More quantitative analysis. Better, faster, cheaper, more accurate. Image analysis and tele-consultation have been and will […]

Continue Reading

Proscia Introduces New Image Analysis Applications – Expands its Pathology Cloud Platform

| October 26, 2016 | 0 Comments

New applications on the platform enable acceleration of breakthroughs in the fight against cancer. Baltimore, MD; San Diego, CA (PRWEB) October 24, 2016 — Proscia Inc, the industry’s leading provider of cloud solutions for digital pathology, announced today the availability of powerful image analysis applications for cancer research on the company’s Proscia Pathology Cloud platform […]

Continue Reading

Case Study using HALO™ and STRATA™: Biomarkers of Anti-Tumor Immune Activity Associate with Survival in Melanoma

| September 19, 2016 | 0 Comments

Wednesday September 28th | 8 AM PDT | 11 AM EDT | 4 PM BST Presenters Dr. Tricia Cottrell, Johns Hopkins Medical School  Vlado Ovtcharov, Indica Labs PD-L1 expression in the tumor microenvironment can be both prognostic and predictive.  PD-L1 expression is often a marker of an ongoing CD8+ cytotoxic T-cell-mediated anti-tumor immune response, and thus, […]

Continue Reading

FDA Grants Accelerated Approval to Nivolumab in Classical Hodgkin Lymphoma

| May 17, 2016 | 0 Comments

More interesting news around PD-L1 for use in Classical Hodgkin lymphoma with specific indications as below. Another increasingly common example of companion diagnostics and personalized immunotherapies. On May 17, 2016, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab (Opdivo; Bristol-Myers Squibb) for the treatment of patients with classical Hodgkin lymphoma that has […]

Continue Reading

Dr. David Rimm Joins Biocept, Inc. as a Scientific Advisor

| March 2, 2015 | 0 Comments

SAN DIEGO, March 2, 2015 (GLOBE NEWSWIRE) — Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today announced that David Rimm, M.D., Ph.D., Professor of Pathology and Professor of Medicine in Medical Oncology at Yale University School of Medicine, will join the […]

Continue Reading